Loss of PTEN can limit the activity of drugs that target p110α particularly in PIK3CA altered tumours, and treatment with PI3Kβ inhibitors overcomes PTEN protein loss mediated resistance12. The gene discussed is PIK3CA; the disease is neoplasm.